Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets
- 8 May 2012
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 166 (3), 806-822
- https://doi.org/10.1111/j.1476-5381.2011.01812.x
Abstract
Monoclonal antibodies (mAbs) and fusion proteins directed towards soluble targets make an important contribution to the treatment of disease. The purpose of this review was to correlate the clinical and preclinical data on the 14 currently approved mAbs and fusion proteins targeted to soluble targets. The principal sources used to gather data were: the peer reviewed Literature; European Medicines Agency 'Scientific Discussions' and United States Food and Drug Administration 'Pharmacology/Toxicology Reviews' and package inserts (United States Prescribing Information). Data on the following approved biopharmaceuticals were included: adalimumab, anakinra, bevacizumab, canakinumab, certolizumab pegol, denosumab, eculizumab, etanercept, golimumab, infliximab, omalizumab, ranibizumab, rilonacept and ustekinumab. Some related biopharmaceuticals in late-stage development were also included for comparison. Good concordance with human pharmacodynamics was found for both non-human primates (NHPs) receiving the human biopharmaceutical and mice receiving rodent homologues (surrogates). In contrast, there was limited concordance for human adverse effects in genetically deficient mice, mice receiving surrogates or NHPs receiving the human pharmaceutical. In summary, the results of this survey show that although both mice and NHPs have good predictive value for human pharmacodynamics, neither species have good predictive value for human adverse effects. No evidence that NHPs have superior predictive value was found.This publication has 150 references indexed in Scilit:
- Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseasesBritish Journal of Pharmacology, 2011
- Treatment of rheumatoid arthritis with tumour necrosis factor inhibitorsBritish Journal of Pharmacology, 2011
- Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safetyRheumatology, 2010
- The complement systemCell and tissue research, 2010
- Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agentsBritish Journal of Pharmacology, 2010
- Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque modelArthritis & Rheumatism, 2010
- Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasisProceedings of the National Academy of Sciences of the United States of America, 2009
- Molecular Diversity of VEGF-A as a Regulator of Its Biological ActivityMicrocirculation, 2009
- Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesisProceedings of the National Academy of Sciences of the United States of America, 2008
- Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient miceProceedings of the National Academy of Sciences of the United States of America, 2006